Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Double Blind, Randomized, Placebo Controlled, Parallel Design Pharmacokinetic Drug Interaction Study of ACH-0143102 and ACH-0142684 in Healthy Volunteers.

Next Previous
Trial Profile

A Phase 1, Double Blind, Randomized, Placebo Controlled, Parallel Design Pharmacokinetic Drug Interaction Study of ACH-0143102 and ACH-0142684 in Healthy Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deldeprevir (Primary) ; Odalasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Achillion Pharmaceuticals

    • Most Recent Events

    • 17 Jul 2014 According to the Australian New Zealand Clinical Trials Registry record, status changed from not yet recruiting to completed.
    • 06 Mar 2014 As per Australian New Zealand Clinical Trials Registry record planned initiation date changed from 1 Mar 2014 to 3 Feb 2014.
    • 06 Mar 2014 As per Australian New Zealand Clinical Trials Registry record trials status changed from planning to not yet recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top